Osterweis Capital Management Inc. Buys Shares of 708,949 Boston Scientific Corporation $BSX

Osterweis Capital Management Inc. bought a new position in shares of Boston Scientific Corporation (NYSE:BSX) in the 2nd quarter, according to its most recent 13F filing with the SEC. The fund bought 708,949 shares of the medical equipment provider’s stock, valued at approximately $30,258,000. Boston Scientific accounts for approximately 1.4% of Osterweis Capital Management Inc.’s holdings, making the stock its 27th biggest holding.

Other institutional investors and hedge funds also recently modified their holdings of the company. BlackRock Inc. acquired a new position in Boston Scientific during the second quarter valued at approximately $5,534,781,000. State Street Corp boosted its position in shares of Boston Scientific by 1.4% during the fourth quarter. State Street Corp now owns 65,846,059 shares of the medical equipment provider’s stock worth $6,278,422,000 after purchasing an additional 920,495 shares in the last quarter. Capital World Investors grew its holdings in shares of Boston Scientific by 1.9% in the 4th quarter. Capital World Investors now owns 27,151,575 shares of the medical equipment provider’s stock valued at $2,588,953,000 after buying an additional 502,627 shares during the period. Norges Bank acquired a new position in shares of Boston Scientific in the 4th quarter valued at $2,199,395,000. Finally, Morgan Stanley increased its position in shares of Boston Scientific by 10.8% in the 4th quarter. Morgan Stanley now owns 22,960,556 shares of the medical equipment provider’s stock valued at $2,189,289,000 after buying an additional 2,246,308 shares in the last quarter. 89.07% of the stock is owned by institutional investors.

Insider Buying and Selling

In other Boston Scientific news, CEO Michael F. Mahoney bought 186,240 shares of the firm’s stock in a transaction that occurred on Monday, August 3rd. The stock was acquired at an average price of $48.33 per share, with a total value of $9,000,979.20. Following the completion of the transaction, the chief executive officer owned 1,590,024 shares in the company, valued at approximately $76,845,859.92. This trade represents a 13.27% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director David C. Habiger purchased 2,100 shares of the stock in a transaction on Wednesday, August 5th. The stock was acquired at an average price of $47.59 per share, for a total transaction of $99,939.00. Following the completion of the purchase, the director directly owned 17,160 shares in the company, valued at approximately $816,644.40. The trade was a 13.94% increase in their position. The SEC filing for this purchase provides additional information. Over the last 90 days, insiders acquired 194,522 shares of company stock worth $9,385,210. 0.34% of the stock is owned by insiders.

Boston Scientific Trading Down 2.8%

NYSE BSX opened at $48.98 on Tuesday. The stock has a market capitalization of $70.99 billion, a price-to-earnings ratio of 19.83, a PEG ratio of 1.10 and a beta of 0.56. The stock’s 50 day moving average price is $46.38 and its two-hundred day moving average price is $57.32. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.74 and a current ratio of 1.24. Boston Scientific Corporation has a 52 week low of $42.20 and a 52 week high of $109.50.

Boston Scientific (NYSE:BSX) last released its quarterly earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share for the quarter, topping analysts’ consensus estimates of $0.83 by $0.03. Boston Scientific had a return on equity of 19.28% and a net margin of 17.50%.The firm had revenue of $5.44 billion during the quarter, compared to the consensus estimate of $5.38 billion. During the same quarter in the prior year, the firm posted $0.75 EPS. The business’s revenue was up 7.5% on a year-over-year basis. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. As a group, analysts anticipate that Boston Scientific Corporation will post 3.3 earnings per share for the current fiscal year.

Boston Scientific announced that its board has initiated a stock repurchase program on Monday, May 18th that authorizes the company to buyback $5.00 billion in outstanding shares. This buyback authorization authorizes the medical equipment provider to buy up to 6.4% of its stock through open market purchases. Stock buyback programs are typically a sign that the company’s board believes its stock is undervalued.

Analyst Ratings Changes

Several research firms have weighed in on BSX. BTIG Research reduced their target price on Boston Scientific from $65.00 to $60.00 and set a “buy” rating on the stock in a report on Wednesday, July 29th. Piper Sandler restated an “overweight” rating and issued a $65.00 price target on shares of Boston Scientific in a report on Friday, June 12th. Zacks Research lowered Boston Scientific from a “hold” rating to a “strong sell” rating in a research report on Friday, June 5th. Mizuho cut their price objective on Boston Scientific from $90.00 to $70.00 and set an “outperform” rating on the stock in a report on Wednesday, July 15th. Finally, Argus reiterated a “hold” rating on shares of Boston Scientific in a research report on Friday, July 31st. Twenty-four analysts have rated the stock with a Buy rating, five have given a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $71.62.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.